Menu Content/Inhalt

Meet with us

BioPharm America 2009 
San Francisco, USA
Sept 16 - 18, 2009

and

BioContact Quebec 2009 
Château Frontenac, Québec, Canada 
October 7-8, 2009 

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. We develop our products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

We independently fund the worldwide development of all of our products while providing expertise in preclinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

The sales turnover of our products through our licensees reached $2.6 billion in 2008.

 

News

23-Jun-2009
Salvacyl®, developed by Debiopharm, is launched in two European countries - a new therapeutic avenue for the treatment of sexual deviations -

18-Jun-2009
Debiopharm Group and Moffitt Cancer Center sign development and commercialisation agreement for small molecule Debio 0928 in early preclinical development for treatment of solid tumours - A novel drug with potential to block cancer cell proliferation

26-May-2009
DiagnoSwiss remporte le "Prix Debiopharm Valais pour les Sciences de la Vie" pour sa technologie de bio-micro-électronique innovante

23-Jun-2009
Salvacyl®, developed by Debiopharm, is launched in two European countries - a new therapeutic avenue for the treatment of sexual deviations -

18-Jun-2009
Debiopharm Group and Moffitt Cancer Center sign development and commercialisation agreement for small molecule Debio 0928 in early preclinical development for treatment of solid tumours - A novel drug with potential to block cancer cell proliferation

26-May-2009
DiagnoSwiss remporte le "Prix Debiopharm Valais pour les Sciences de la Vie" pour sa technologie de bio-micro-électronique innovante

23-Jun-2009
Salvacyl®, developed by Debiopharm, is launched in two European countries - a new therapeutic avenue for the treatment of sexual deviations -

18-Jun-2009
Debiopharm Group and Moffitt Cancer Center sign development and commercialisation agreement for small molecule Debio 0928 in early preclinical development for treatment of solid tumours - A novel drug with potential to block cancer cell proliferation

26-May-2009
DiagnoSwiss remporte le "Prix Debiopharm Valais pour les Sciences de la Vie" pour sa technologie de bio-micro-électronique innovante